Telomir CEO swaps options for lower strike awards
Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov reported changes to his stock option awards.
Rhea-AI Filing Summary
Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov reported changes to his stock option awards. On May 21, 2026, he agreed to cancel previously granted options for 2,000,000 shares of common stock at a $2.10 exercise price and 1,960,170 shares at $5.02, both through dispositions to the issuer. In exchange, he received fully exercisable new options covering the same share amounts at a lower $1.30 exercise price, with expirations in 2036. The filing also shows he holds 7,319,710 common shares directly after these transactions, and it does not report any open‑market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Aminov Erez
Role
CEO and Chairman
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Incentive Stock Options (right to buy) | 1,960,170 | $0.00 | $0.00 |
| Disposition | Incentive Stock Options (right to buy) | 1,960,170 | $0.00 | $0.00 |
| Grant/Award | Non-Qualified Stock Options (right to buy) | 2,000,000 | $0.00 | $0.00 |
| Disposition | Non-Qualified Stock Options (right to buy) | 2,000,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Incentive Stock Options (right to buy) — 1,960,170 contracts (Direct);
Non-Qualified Stock Options (right to buy) — 2,000,000 contracts (Direct);
Common Stock — 7,319,710 shares (Direct)
Footnotes (2)
- F1. The options are fully exercisable.
- F2. The reporting person agreed to cancellation of options granted to him on 08/27/2024 and 05/27/2025, in exchange for new options having a lower exercise price.
Key Figures
Common shares held: 7,319,710 shares
Canceled non-qualified options: 2,000,000 options at $2.10
New non-qualified options: 2,000,000 options at $1.30
+3 more
6 metrics
Common shares held
7,319,710 shares
Direct ownership after transactions on May 21, 2026
Canceled non-qualified options
2,000,000 options at $2.10
Disposition to issuer; underlying common stock
New non-qualified options
2,000,000 options at $1.30
Grant, fully exercisable, expiring May 21, 2036
Canceled incentive options
1,960,170 options at $5.02
Disposition to issuer; underlying common stock
New incentive options
1,960,170 options at $1.30
Grant, fully exercisable, expiring May 21, 2036
Derivative transactions
4 transactions
Two dispositions and two grants of stock options
Key Terms
Non-Qualified Stock Options, Incentive Stock Options, Disposition to issuer, Grant, award, or other acquisition, +1 more
5 terms
Non-Qualified Stock Options financial
"Non-Qualified Stock Options (right to buy)"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Incentive Stock Options financial
"Incentive Stock Options (right to buy)"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
Disposition to issuer financial
"transaction_action": "issuer disposition""
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
fully exercisable financial
"The options are fully exercisable."
FAQ
What insider transactions did Telomir Pharmaceuticals (TELO) report for CEO Erez Aminov?
Telomir’s CEO Erez Aminov reported canceling earlier stock options and receiving new fully exercisable options on the same number of shares at a lower $1.30 exercise price, with no open-market purchases or sales disclosed in this filing.
How many Telomir Pharmaceuticals (TELO) options were canceled and regranted in this Form 4?
Options for 2,000,000 common shares at a $2.10 exercise price and 1,960,170 shares at $5.02 were canceled. Matching new options for 2,000,000 and 1,960,170 shares were granted at a lower $1.30 exercise price to replace the canceled awards.
Did Telomir Pharmaceuticals (TELO) CEO buy or sell common stock in this Form 4?
The Form 4 does not show any open-market purchases or sales of common stock. It reports option cancellations and new option grants, while Aminov’s direct common stock holdings stand at 7,319,710 shares following these derivative transactions.
What are the new exercise prices and expirations for Telomir Pharmaceuticals (TELO) CEO options?
The new Non-Qualified and Incentive Stock Options each carry a $1.30 exercise price. The replacement awards for 2,000,000 and 1,960,170 underlying shares are scheduled to expire on May 21, 2036, according to the reported transaction details.
Why were Telomir Pharmaceuticals (TELO) CEO stock options canceled and reissued?
The filing states that Aminov agreed to cancel options granted on August 27, 2024 and May 27, 2025. In exchange, he received new options with a lower $1.30 exercise price, effectively repricing his equity incentives without changing the number of underlying shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
